Good morning :)
$
₹
Pulmonx Corp

Pulmonx Corp

LUNG

NASDAQ
Asset Logo

Pulmonx Corp

LUNG

NASDAQ
$1.922.28% (-0.04)
$
₹
$1.922.28% (-0.04)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
Loading...
1D
1W
1M
1Y
5Y
Max

Healthcare

Medical Devices

Micro Cap

With a market cap of $79.5M the stock is ranked 4850

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

—
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

2.02
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$-1.15
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

—
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

-55.03%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

—

Analyst Ratings & Forecast
Analyst Ratings & Forecast

Based on 7 analysts' reports

Buy
5 analysts
Hold
2 analysts
Sell
0 analyst

Analysts expect a +78.01% price upside over the next year

Current Price$1.92
Target Price$3.4

Company Profile

Pulmonx Corporation, a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease. It offers Zephyr Endobronchial Valve; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also offers LungTraX Platform, a cloud-based quantitative computed tomography analysis service that provides physicians with multiple products, such as LungTraX Connect to improve workup efficiency; LungTraX Detect to enable patient identification; and StratX Lung report that is designed for solution that includes information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for treatment with Zephyr Valves. It serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.
Pulmonx Corporation, a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease. It offers Zephyr Endobronchial Valve; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also offers LungTraX Platform, a cloud-based quantitative computed tomography analysis service that provides physicians with multiple products, such as LungTraX Connect to improve workup efficiency; LungTraX Detect to enable patient identification; and StratX Lung report that is designed for solution that includes information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for treatment with Zephyr Valves. It serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.

Peers

Peers

Abbott Laboratories
ABT
Abbott Laboratories
P/E Ratio
32.99
32.99
1Y Return
21.15%
21.15%
Buy Reco %
74.07
74.07
Danaher Corporation
DHR
Danaher Corporation
P/E Ratio
35.73
35.73
1Y Return
11.23%
11.23%
Buy Reco %
88.00
88.00
Intuitive Surgical Inc
ISRG
Intuitive Surgical Inc
P/E Ratio
42.38
42.38
1Y Return
13.09%
13.09%
Buy Reco %
66.66
66.66
Medtronic PLC
MDT
Medtronic PLC
P/E Ratio
22.40
22.40
1Y Return
1.1%
1.1%
Buy Reco %
53.12
53.12
Stryker Corporation
SYK
Stryker Corporation
P/E Ratio
28.58
28.58
1Y Return
25.18%
25.18%
Buy Reco %
68.75
68.75

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareMedical Devices

Valuation

Returns

Forecast

StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
Pulmonx Corp -2.02-
Abbott Laboratories32.993.451.87
Danaher Corporation35.732.671.19

Price Comparison

Price Comparison

1 Month

1 Year

5 Years

Loading...

Financials

Financials

Income

Balance Sheet

Cash Flow

21.5
-13.9
22.5
-10.4
20.5
-13.6
22.7
-10
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Revenue
Net Income
Financial YearQ1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026
Total Revenue18.8520.7820.3823.7622.5323.8521.5022.5920.5822.75
Net Income-13.74-15.32-14.14-13.17-14.44-15.17-13.95-10.42-13.65-10.08
Net Profit Margin-72.92%-73.74%-69.37%-55.43%-64.10%-63.59%-64.91%-46.13%-66.32%-44.29%
See CostsAll values in $ Million

Frequently asked questions

Frequently asked questions

  1. Pulmonx Corp (LUNG) share price today is $1.92 as of September 16, 2026 at 1:30 AM IST. The stock touched a day high of $1.99 and a day low of $1.91.

  2. Pulmonx Corp stock trades on NASDAQ under the ticker symbol LUNG.

  3. Pulmonx Corp's market capitalization is $79.45M as of September 16, 2026 at 1:30 AM IST.

  4. Pulmonx Corp's price-to-earnings (P/E) ratio is N/A as of September 15, 2026.

  5. Pulmonx Corp's price-to-book (P/B) ratio is 2.02 as of September 15, 2026.

  6. Yes, You can buy Pulmonx Corp shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  7. Indian investors can buy Pulmonx Corp shares in three steps: 1. Search Pulmonx Corp on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  8. Since Pulmonx Corp trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  9. Indian investors can start investing in Pulmonx Corp (LUNG) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 5.1948 shares at the current price of $1.92.

Loading...